This press release was issued by Edwards Lifesciences.
Edwards Lifesciences (“Edwards”) today celebrated 20 years in Singapore with its employees at the company’s Changi facility, marking a milestone in its partnership with Singapore’s healthcare and manufacturing communities.
Edwards’ Singapore facility plays a vital role in supporting the rising need for heart valve therapies for cardiovascular disease, which is a significant health challenge, accounting for more than half of all global CVD deaths . Since establishing its Singapore operations in 2005, the company has collaborated with the country’s medical technology ecosystem to advance innovation and technical excellence, thereby improving patient access to life-saving heart valve treatments.
